Aliases & Classifications for Bronchiectasis

MalaCards integrated aliases for Bronchiectasis:

Name: Bronchiectasis 12 72 28 51 41 14 69 59
Polynesian Bronchiectasis 12
Kartagener Syndrome 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9563
ICD10 32 J47 J47.9
ICD9CM 34 494
MeSH 41 D001987
NCIt 46 C84475
UMLS 69 C0006267

Summaries for Bronchiectasis

PubMed Health : 59
About bronchiectasis: Bronchiectasis (brong-ke-EK-tah-sis) is a condition in which damage to the airways causes them to widen and become flabby and scarred. The airways are tubes that carry air in and out of your lungs.Bronchiectasis often is caused by an infection or other condition that injures the walls of the airways or prevents the airways from clearing mucus. Mucus is a slimy substance. It helps remove inhaled dust, bacteria, and other small particles from the airways.In bronchiectasis, your airways slowly lose their ability to clear out mucus. The mucus builds up, and bacteria begin to grow. This leads to repeated, serious lung infections.Each infection causes more damage to the airways. Over time, the airways can't properly move air in and out of the lungs. As a result, the body's vital organs might not get enough oxygen.Bronchiectasis can lead to serious health problems, such as respiratory failure, atelectasis (at-eh-LEK-tah-sis), and heart failure.

MalaCards based summary : Bronchiectasis, also known as polynesian bronchiectasis, is related to bronchiectasis with or without elevated sweat chloride 1 and idiopathic bronchiectasis, and has symptoms including headache An important gene associated with Bronchiectasis is SCNN1B (Sodium Channel Epithelial 1 Beta Subunit), and among its related pathways/superpathways are Innate Immune System and Neuropathic Pain-Signaling in Dorsal Horn Neurons. The drugs Amikacin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and neutrophil, and related phenotypes are immune system and renal/urinary system

Disease Ontology : 12 A bronchial disease that is a chronic inflammatory condition of one or more bronchi or bronchioles marked by dilatation and loss of elasticity of the walls resulting from damage to the airway wall leading to the formation of small sacs on the bronchial wall and impairment of cilia mobility in the lung. Inflammation of the bronchial wall increases mucus secretion which serves as a breeding ground for bacteria. Bronchiectasis is caused by repeated respiratory infections, immune deficiency disorders, hereditary disorders (cystic fibrosis or primary ciliary dyskinesia), mechanical factors (inhaled object or a lung tumor) or inhaling toxic substances.

Wikipedia : 72 Bronchiectasis is a disease in which there is permanent enlargement of parts of the airways of the lung.... more...

Related Diseases for Bronchiectasis

Diseases related to Bronchiectasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 247)
# Related Disease Score Top Affiliating Genes
1 bronchiectasis with or without elevated sweat chloride 1 34.1 CFTR SCNN1B
2 idiopathic bronchiectasis 33.6 CFTR SCNN1A SCNN1B SCNN1G
3 kartagener syndrome 32.9 CFTR DNAH5 DNAI1
4 primary ciliary dyskinesia 31.3 CFTR CXCL8 DNAH5 DNAI1 MBL2
5 nontuberculous mycobacterial lung disease 31.2 CFTR TLR2
6 pulmonary disease, chronic obstructive 30.5 CXCL8 ELANE SERPINA1
7 anca-associated vasculitis 29.7 MPO SERPINA1
8 haemophilus influenzae 29.6 CXCL8 TLR2
9 bronchitis 29.6 CFTR CXCL8 ELANE MPO SERPINA1
10 pulmonary emphysema 29.5 ELANE MMP8 SERPINA1
11 crescentic glomerulonephritis 29.4 BPI CTSG MPO
12 bronchopneumonia 29.3 ELANE MPO
13 lung disease 29.3 CFTR CTSG CXCL8 ELANE MPO SERPINA1
14 aspergillosis 29.2 CFTR ELANE MBL2 TLR2
15 ulcerative colitis 29.1 BPI CXCL8 MPO
16 mycobacterium abscessus 29.0 CFTR CXCL8 SERPINA1 TLR2
17 vasculitis 28.9 BPI CTSG ELANE MPO SERPINA1
18 cystic fibrosis 28.9 BPI CFTR CTSG CXCL8 ELANE MBL2
19 sclerosing cholangitis 28.9 BPI CFTR CTSG MPO
20 periodontitis 28.7 CXCL8 ELANE MMP8 TLR2
21 pneumonia 28.7 CXCL8 ELANE MBL2 MPO TLR2
22 alpha-1-antitrypsin deficiency 28.6 BPI CFTR CXCL8 ELANE SERPINA1 SERPINA3
23 bronchiectasis with or without elevated sweat chloride 2 12.2
24 bronchiectasis with or without elevated sweat chloride 3 12.2
25 ciliary dyskinesia-bronchiectasis 12.0
26 bronchiectasis oligospermia 11.9
27 ciliary dyskinesia, primary, 1 11.7
28 yellow nail syndrome 11.2
29 panbronchiolitis, diffuse 11.2
30 tracheobronchomegaly 11.0
31 ciliary dyskinesia, primary, 25 10.9
32 ciliary dyskinesia, primary, 26 10.9
33 ciliary dyskinesia, primary, 27 10.9
34 ciliary dyskinesia, primary, 28 10.9
35 ciliary dyskinesia, primary, 32 10.9
36 cutis laxa, autosomal dominant 1 10.9
37 young syndrome 10.9
38 ciliary dyskinesia, primary, 9 10.9
39 ciliary dyskinesia, primary, 11 10.9
40 ciliary dyskinesia, primary, 12 10.9
41 ciliary dyskinesia, primary, 22 10.9
42 ciliary dyskinesia, primary, 23 10.9
43 ciliary dyskinesia, primary, 30 10.9
44 ciliary dyskinesia, primary, 36, x-linked 10.7
45 bare lymphocyte syndrome, type i 10.7
46 ciliary dyskinesia, primary, 2 10.7
47 ciliary dyskinesia, primary, 3 10.7
48 ciliary dyskinesia, primary, 5 10.7
49 ciliary dyskinesia, primary, 6 10.7
50 ciliary dyskinesia, primary, 7 10.7

Comorbidity relations with Bronchiectasis via Phenotypic Disease Network (PDN): (show all 20)


Agammaglobulinemia, X-Linked Anxiety
Aspergillosis Bronchitis
Bronchopneumonia Chronic Pulmonary Heart Disease
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hypothyroidism Idiopathic Interstitial Pneumonia
Lung Abscess Mitral Valve Disease
Osteoporosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Pulmonary Tuberculosis
Respiratory Failure Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Bronchiectasis:



Diseases related to Bronchiectasis

Symptoms & Phenotypes for Bronchiectasis

UMLS symptoms related to Bronchiectasis:


headache

MGI Mouse Phenotypes related to Bronchiectasis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.81 MBL2 MMP8 MPO TLR2 CFTR CTSG
2 renal/urinary system MP:0005367 9.43 DNAH5 MBL2 SCNN1A SCNN1B SCNN1G TLR2
3 respiratory system MP:0005388 9.17 CFTR DNAH5 DNAI1 SCNN1A SCNN1B SCNN1G

Drugs & Therapeutics for Bronchiectasis

PubMedHealth treatment related to Bronchiectasis: 59

Bronchiectasis often is treated with medicines, hydration, and chest physical therapy (CPT). Your doctor may recommend surgery if the bronchiectasis is isolated to a section of lung or you have a lot of bleeding.If the bronchiectasis is widespread and causing respiratory failure, your doctor may recommend oxygen therapy.The goals of treatment are to:Treat any underlying conditions and lung infections.Remove mucus (a slimy substance) from your lungs. Maintaining good hydration helps with mucus removal.Prevent complications.Early diagnosis and treatment of the underlying cause of bronchiectasis may help prevent further lung damage. In addition, any disease associated with the bronchiectasis, such as cystic fibrosis or immunodeficiency, also should be treated.

Drugs for Bronchiectasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amikacin Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 37517-28-5 37768
2
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 83905-01-5 53477736 447043 55185
3
Tobramycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 32986-56-4 36294 5496
4
Theophylline Approved Phase 4 58-55-9 2153
5
Budesonide Approved Phase 4 51333-22-3 5281004 63006
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
7
Meropenem Approved, Investigational Phase 4 119478-56-7 441130 64778
8
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
10
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 10883523 5280795 6221
11
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
12 Respiratory System Agents Phase 4,Phase 2
13 Micronutrients Phase 4
14 Neurotransmitter Agents Phase 4
15 Trace Elements Phase 4
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3
17 Vaccines Phase 4,Phase 3
18 Vasodilator Agents Phase 4
19 Vitamins Phase 4
20 Peripheral Nervous System Agents Phase 4,Phase 2
21 Anti-Asthmatic Agents Phase 4,Phase 2
22 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Ergocalciferols Phase 4
24 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Immunoglobulins Phase 4,Phase 3
27 Protective Agents Phase 4,Phase 1
28 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
29 Antibodies Phase 4,Phase 3
30 Antioxidants Phase 4
31 Autonomic Agents Phase 4,Phase 2
32 Bone Density Conservation Agents Phase 4
33 Bronchodilator Agents Phase 4,Phase 2
34
Salmeterol xinafoate Phase 4 94749-08-3 56801
35 Atorvastatin Calcium Phase 4 134523-03-8
36
Fluticasone Phase 4,Phase 2 80474-14-2, 90566-53-3 22833648 62924
37 glucocorticoids Phase 4
38 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4
39 Adrenergic Agents Phase 4
40 Adrenergic Agonists Phase 4
41 Adrenergic beta-2 Receptor Agonists Phase 4
42 Adrenergic beta-Agonists Phase 4
43 Formoterol Fumarate Phase 4
44 Gentamicins Phase 4
45 Hormone Antagonists Phase 4
46 Dermatologic Agents Phase 4,Phase 2
47 Hormones Phase 4
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
49 Anti-Allergic Agents Phase 4,Phase 2
50 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 234)

# Name Status NCT ID Phase Drugs
1 A Study to Access Safety and Efficacy of Nebulized Tobramycin in Patients With Bronchiectasis Unknown status NCT01677403 Phase 4 Tobramycin;Saline
2 Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis Unknown status NCT02507843 Phase 4 Cholecalciferol;Placebo
3 Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis Unknown status NCT02081963 Phase 4 Amikacin;Normal saline
4 Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) Unknown status NCT01830959 Phase 4 Roflumilast;Placebo
5 Polysaccharide Antibody Response Study Unknown status NCT02429531 Phase 4
6 Prevention of OM-85 on Bronchiectasis Exacerbation Completed NCT01968421 Phase 4 OM-85
7 Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis Completed NCT02782312 Phase 4 ICS+LABA
8 The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis Completed NCT01769898 Phase 4 Formoterol-budesonide;Theophylline;Placebo
9 Efficacy of Azithromycin in Treatment of Bronchiectasis Completed NCT02107274 Phase 4 Azithromycin;Placebo for Azithromycin
10 Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis? Completed NCT00816309 Phase 4
11 The Effect of Theophylline in the Treatment of Bronchiectasis Completed NCT01684683 Phase 4 Theophylline;Placebo(for Theophylline)
12 Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa Completed NCT01299194 Phase 4 ATORVASTATIN
13 A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis Completed NCT01299181 Phase 4 Atorvastatin
14 Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis Completed NCT00868075 Phase 4
15 Long Term Nebulised Gentamicin in Patients With Bronchiectasis Completed NCT00749866 Phase 4 Gentamicin;Saline
16 Effectiveness and Safety of Inhaling Hypertonic Saline in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00639236 Phase 4
17 Efficacy of Temporary Positive Expiratory Pressure (TPEP) in Chronic Hypersecretion Completed NCT00700388 Phase 4
18 Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations Recruiting NCT02047773 Phase 4 Colomycin;Meropenem
19 Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis Recruiting NCT02509091 Phase 4 Bronchoalveolar Lavage and Local Amikacin Injection
20 Comparisons of Inhaled LAMA or ICS+LABA for COPD With Bronchiectasis Recruiting NCT02546297 Phase 4 Symbicort;Tiotropium Bromide
21 Evaluating the Effects of Traditional Chinese Medicine by N-of-1 Trials Recruiting NCT03147443 Phase 4 Individualized Decoction;placebo;Tested drug minus heat-clearing herbs
22 Hospitalised Pneumonia With Extended Treatment (HOPE) Study Recruiting NCT02783859 Phase 4 Amoxicillin-clavulanic Acid;Placebo (for Amoxicillin-clavulanic Acid)
23 Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis Active, not recruiting NCT02088216 Phase 4 N-acetylcysteine;Placebo
24 VX-770 for the Treatment of Chronic Bronchitis Not yet recruiting NCT03251911 Phase 4 Ivacaftor (VX-770)
25 "Nebulized N-Acetyl Cysteine for Bronchiolitis in Inpatient Hospital Use: A Randomized Controlled Trial" Inpatient Hospital Use: A Randomized Controlled Trial" Not yet recruiting NCT03364218 Phase 4 N acetyl cysteine nebulized
26 Bronchiectasis and Long Term Azithromycin Treatment Unknown status NCT00415350 Phase 3 Azithromycin
27 The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis Unknown status NCT01496196 Phase 3 tranexamic acid;tranexamic acid
28 An Open Label Trial of Azithromycin in Chronic Productive Cough Unknown status NCT02196493 Phase 3 Azithromycin
29 Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Completed NCT02106832 Phase 3 Ciprofloxacin (BAYQ3939) dry powder for inhalation;Ciprofloxacin (BAYQ3939) dry powder for inhalation;Placebo;Placebo
30 Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4) Completed NCT02104245 Phase 3 Ciprofloxacin dispersion for inhalation;Placebo
31 Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Completed NCT01764841 Phase 3 Ciprofloxacin DPI (BAYQ3939);Placebo
32 Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3) Completed NCT01515007 Phase 3 Ciprofloxacin dispersion for inhalation;Placebo
33 Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis Completed NCT00669331 Phase 3 Inhaled mannitol;Matched control
34 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis Completed NCT01313624 Phase 3 AZLI;Placebo
35 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis Completed NCT01314716 Phase 3 AZLI;Placebo
36 The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis Completed NCT00484263 Phase 3 Hypertonic saline 6% -
37 Safety and Efficacy of Bronchitol in Bronchiectasis Completed NCT00277537 Phase 3 Mannitol;placebo
38 Efficacy and Safety Study of a Percussion Device to Mobilise Sputum From Respiratory Passage Completed NCT01480882 Phase 2, Phase 3
39 Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) Completed NCT00656409 Phase 3 Conjugated pneumococcal vaccine (Prevenar)
40 EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection Completed NCT00105183 Phase 3
41 Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher Completed NCT00380315 Phase 3 AG1321001(drug)
42 Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF Completed NCT01641822 Phase 3 AZLI;Placebo to match AZLI;Tobramycin inhalation solution
43 Prevention of Bronchiectasis in Infants With Cystic Fibrosis Recruiting NCT01270074 Phase 3 Azithromycin;Placebo control
44 Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis Recruiting NCT02657473 Phase 2, Phase 3 tobramycin inhalation solution;Saline 0.9% inhalation solution
45 Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium Recruiting NCT03093974 Phase 3 Colistimethate Sodium;Saline Solution
46 The Efficacy of Azithromycin in Treating Children With Non Cystic Fibrosis Bronchiectasis Active, not recruiting NCT02531984 Phase 3 Azithromycin
47 Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization Active, not recruiting NCT01973998 Phase 3 Roflumilast;Placebo
48 Effects of Traditional Chinese Medicine on Bronchiectasis Patients Not yet recruiting NCT03443531 Phase 3 Bufei Huatan granule;Yifei Qinghua granule;Placebo Bufei Huatan granule;Placebo Yifei Qinghua granule
49 Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Bronchiectasis Unknown status NCT01112410 Phase 2
50 Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients Unknown status NCT01580748 Phase 2 Roflumilast

Search NIH Clinical Center for Bronchiectasis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: bronchiectasis

Genetic Tests for Bronchiectasis

Genetic tests related to Bronchiectasis:

# Genetic test Affiliating Genes
1 Bronchiectasis 28

Anatomical Context for Bronchiectasis

MalaCards organs/tissues related to Bronchiectasis:

38
Lung, Heart, Neutrophil, Testes, Colon, Bone, Liver

Publications for Bronchiectasis

Articles related to Bronchiectasis:

(show top 50) (show all 810)
# Title Authors Year
1
Subclinical atherosclerosis in adults with steady-state bronchiectasis: A case-control study. ( 29413496 )
2018
2
The independent contribution of<i>Pseudomonas aeruginosa</i>infection to long-term clinical outcomes in bronchiectasis. ( 29386336 )
2018
3
Hip Fracture and Palpitations in a 92-Year-Old Woman With Bronchiectasis. ( 29450461 )
2018
4
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. ( 29371384 )
2018
5
Upper airway involvement in bronchiectasis is marked by early onset and allergic features. ( 29362708 )
2018
6
<i>Pseudomonas aeruginosa</i> infection and exacerbations in bronchiectasis: more questions than answers. ( 29386340 )
2018
7
Association between I+<sub>1</sub>-antitrypsin and bronchiectasis in patients with humoral immunodeficiency receiving gammaglobulin infusions. ( 29413345 )
2018
8
Antibiotic-resistant<i>Pseudomonas aeruginosa</i>infection in patients with bronchiectasis: prevalence, risk factors and prognostic implications. ( 29386892 )
2018
9
Atorvastatin in Bronchiectasis With Chronic Pseudomonas Infection. ( 29406230 )
2018
10
Aspergillus fumigatus Detection and Risk Factors in Patients with COPD-Bronchiectasis Overlap. ( 29425123 )
2018
11
Self-management for bronchiectasis. ( 29411860 )
2018
12
Clinical Determinants of Incremental Shuttle Walk Test in Adults with Bronchiectasis. ( 29435737 )
2018
13
Bronchiectasis: Phenotyping an Orphan Disease. ( 29412693 )
2018
14
Emphysema and bronchiectasis in COPD patients with previous pulmonary tuberculosis: computed tomography features and clinical implications. ( 29416328 )
2018
15
RESPIRE: breathing new life into bronchiectasis. ( 29371393 )
2018
16
Effects of exercise on secretion transport, inflammation, and quality of life in patients with noncystic fibrosis bronchiectasis: Protocol for a randomized controlled trial. ( 29443739 )
2018
17
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. ( 29371383 )
2018
18
Inhaled medication therapy for bronchiectasis: status quo and the next frontier. ( 29425474 )
2018
19
Nasal Nitric Oxide Measurement and a Modified PICADAR Score for the Screening of Primary Ciliary Dyskinesia in Adults with Bronchiectasis. ( 28783864 )
2017
20
Bronchiectasis Complicating Lung Volume Reduction Coil Treatment. ( 28889896 )
2017
21
De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. ( 28889888 )
2017
22
Could Chinese herbs accelerate the resolution of reversible bronchiectasis in adults?: A case report. ( 29390276 )
2017
23
Microbial Dysbiosis in Bronchiectasis and Cystic Fibrosis. ( 28069292 )
2017
24
Residual volume/total lung capacity ratio confers limited additive significance to lung clearance index for assessment of adults with bronchiectasis. ( 28886040 )
2017
25
Successful treatment of pulmonary nocardiosis with fluoroquinolone in bronchial asthma and bronchiectasis. ( 28352469 )
2017
26
Differences of lung microbiome in patients with clinically stable and exacerbated bronchiectasis. ( 28829833 )
2017
27
Two cases of non-cystic fibrosis (CF) bronchiectasis with allergic bronchopulmonary aspergillosis. ( 28053855 )
2017
28
Diffuse bronchiectasis as the primary manifestation of endobronchial sarcoidosis. ( 27896060 )
2017
29
Is treatment of serological ABPA similar to that of ABPA with bronchiectasis? ( 28888259 )
2017
30
Diagnosis of bronchiectasis and airway wall thickening in children with cystic fibrosis: Objective airway-artery quantification. ( 28523349 )
2017
31
European Respiratory Society guidelines for the management of adult bronchiectasis. ( 28889110 )
2017
32
Serum Albumin and Disease Severity of Non-Cystic Fibrosis Bronchiectasis. ( 28512120 )
2017
33
A Full-Blown Case of Bronchiectasis: Kartagener Syndrome Without Infertility Diagnosed Later in Life. ( 29152435 )
2017
34
Bronchiectasis is highly prevalent in anti-MPO ANCA-associated vasculitis and is associated with a distinct disease presentation. ( 29336783 )
2017
35
Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways. ( 28516246 )
2017
36
Does home-based pulmonary rehabilitation improve functional capacity, peripheral muscle strength and quality of life in patients with bronchiectasis compared to standard care? ( 28869119 )
2017
37
The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration. ( 28894479 )
2017
38
The quantitative link of lung clearance index to bronchial segments affected by bronchiectasis. ( 28866642 )
2017
39
Sugar coating bronchiectasis. ( 28070016 )
2017
40
Molecular epidemiology of Pseudomonas aeruginosa in an unsegregated bronchiectasis cohort sharing hospital facilities with a cystic fibrosis cohort. ( 28844058 )
2017
41
The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis. ( 28808486 )
2017
42
Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. ( 28952156 )
2017
43
Promoting Physical Activity Using The Internet: Is It Feasible And Acceptable For Patients With Chronic Obstructive Pulmonary Disease (COPD) And Bronchiectasis? ( 28952865 )
2017
44
Ochroconis gallopava bronchitis mimicking haemoptysis in a patient with bronchiectasis. ( 28884072 )
2017
45
Improving the management of people with bronchiectasis in Saudi: A new beginning. ( 28808485 )
2017
46
Sensitization to Aspergillus fumigatus as a risk factor for bronchiectasis in COPD. ( 28919731 )
2017
47
Editorial: Chronic Suppurative Lung Disease and Bronchiectasis in Children and Adolescents. ( 28929095 )
2017
48
Anxiety and depression in adult outpatients with bronchiectasis: Associations with disease severity and health-related quality of life. ( 28842946 )
2017
49
The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis. ( 28863927 )
2017
50
Role of vitamin D in cystic fibrosis and non-cystic fibrosis bronchiectasis. ( 28828295 )
2017

Variations for Bronchiectasis

Expression for Bronchiectasis

Search GEO for disease gene expression data for Bronchiectasis.

Pathways for Bronchiectasis

GO Terms for Bronchiectasis

Cellular components related to Bronchiectasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 BPI CTSG CXCL8 ELANE MBL2 MMP8
2 extracellular exosome GO:0070062 9.96 BPI CFTR CTSG ELANE MPO SCNN1A
3 cell surface GO:0009986 9.85 CFTR CTSG ELANE MBL2 TLR2
4 extracellular space GO:0005615 9.81 BPI CTSG CXCL8 ELANE MBL2 MMP8
5 apical plasma membrane GO:0016324 9.78 CFTR SCNN1A SCNN1B SCNN1G
6 secretory granule GO:0030141 9.61 CTSG ELANE MPO
7 specific granule lumen GO:0035580 9.54 BPI ELANE MMP8
8 outer dynein arm GO:0036157 9.4 DNAH5 DNAI1
9 sodium channel complex GO:0034706 9.13 SCNN1A SCNN1B SCNN1G
10 azurophil granule lumen GO:0035578 9.02 BPI CTSG ELANE MPO SERPINA3

Biological processes related to Bronchiectasis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.8 CTSG ELANE MPO TLR2
2 neutrophil degranulation GO:0043312 9.76 BPI CTSG ELANE MMP8 MPO SERPINA1
3 sodium ion transport GO:0006814 9.75 SCNN1A SCNN1B SCNN1G
4 defense response to Gram-positive bacterium GO:0050830 9.73 CTSG MBL2 TLR2
5 defense response to bacterium GO:0042742 9.72 BPI CTSG ELANE MBL2 MPO
6 sodium ion transmembrane transport GO:0035725 9.71 SCNN1A SCNN1B SCNN1G
7 extracellular matrix disassembly GO:0022617 9.69 CTSG ELANE MMP8
8 antimicrobial humoral response GO:0019730 9.65 BPI CTSG ELANE
9 sensory perception of taste GO:0050909 9.61 SCNN1A SCNN1B SCNN1G
10 acute-phase response GO:0006953 9.58 MBL2 SERPINA1 SERPINA3
11 outer dynein arm assembly GO:0036158 9.57 DNAH5 DNAI1
12 response to molecule of bacterial origin GO:0002237 9.55 CXCL8 TLR2
13 defense response to fungus GO:0050832 9.54 CTSG ELANE MPO
14 positive regulation of immune response GO:0050778 9.52 CTSG ELANE
15 response to yeast GO:0001878 9.46 ELANE MPO
16 sodium ion homeostasis GO:0055078 9.43 SCNN1A SCNN1B SCNN1G
17 negative regulation of growth of symbiont in host GO:0044130 9.26 CTSG ELANE MBL2 MPO
18 multicellular organismal water homeostasis GO:0050891 8.92 CFTR SCNN1A SCNN1B SCNN1G

Molecular functions related to Bronchiectasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.46 CTSG ELANE MBL2 MMP8
2 dynein light chain binding GO:0045503 9.26 DNAH5 DNAI1
3 WW domain binding GO:0050699 9.13 SCNN1A SCNN1B SCNN1G
4 ligand-gated sodium channel activity GO:0015280 8.8 SCNN1A SCNN1B SCNN1G

Sources for Bronchiectasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....